Company: Afya

Ticker: AFYA

Renata Couto: I'm here today with Afya CEO, Virgílio Gibbon, and our CFO, Luis André Blanco. During today's presentation, our executives will make forward-looking statements. Forward-looking statements can be related to future events, future financial or operating performance, known and unknown risks, uncertainties, and other factors that may cause Afya's actual results to differ materially from those contemplated by these forward-looking statements. Forward-looking statements in this presentation include, but are not limited to, statements related to the business and financial performance, expectations and guidance for future periods, or expectations regarding the company's strategic product initiatives and its related benefits. These risks include those more fully described in our filings with the Securities and Exchange Commission. The forward-looking statements in this presentation are based on the information available to us as the date hereof.

Renata Couto: You should not rely on them as predictions of future events, and we disclaim any obligation to update any forward-looking statement except as required by law. In addition, management may reference non-IFRS measures on this call. These measures are not intended to be considered in isolation or as a substitute for the results prepared in accordance with IFRS. This presentation reconciles these non-IFRS financial measures to the most directly comparable IFRS financial measures. Now, let me turn the call over to Virgílio Gibbon, Afya's CEO.

Virgílio Gibbon: Thank you, Renata, and everyone for joining us today for our Q3 nine months conference call for 2026 results. This quarter reflects more than financial performance. It demonstrates how our strategy continues to position Afya for sustainable growth, transforming medical education across Brazil. As we continue to train physicians with recognized quality and important accreditations and recognitions, such as SAEME, WFME, and MSCI rating, while maintaining 100% occupancy across all of our medical programs in Brazil. Today, I will cover key strategic developments and operational highlights that drove these results. Luis Blanco will provide a detailed review of our operational and financial performance. Let us begin with our main highlights and strategic priorities for the quarter. In Q3, revenue increased 6% year-over-year to BRL 985 million, while adjusted EBITDA increased 9% to BRL 434 million.

Virgílio Gibbon: Adjusted EBITDA margin reached 44%, an expansion of 100 basis points compared to the same period of the prior year. For the first nine months of 2026, revenue grew almost 7% year-over-year, reaching BRL 2,970 million, followed by an adjusted EBITDA growth of almost 5%, reaching BRL 1.3 billion, with an adjusted EBITDA margin of 45.5%. Net income reached BRL 634 million, a 7% increase year-over-year, and basic EPS climbed to BRL 6.98, representing a 9% increase, reflecting the impact of the company's share repurchase program. We also reported a strong operational cash conversion of 99.5%, with BRL 629 million of free cash flow to equity in the nine months of 2026, of which BRL 206 million were generated in Q3 2026. These results reflect the strength of our cash generation, disciplined execution, and our continued commitment to creating long-term shareholder value. Moving now to our operational updates.

Virgílio Gibbon: In this quarter, we maintain our leadership position in medical education, supported by 3,785 operating medical seats, reflecting an increase of over 5% year-over-year. Furthermore, the number of undergrad medical students reached more than 26,000 students, representing 3% growth compared to the same period of the prior year. Additionally, we increased the net average tickets of medical school by 4% year-over-year, reaching BRL 9,466. In Continuing Education, revenue increased 1% over last year, reaching BRL 209 million. In Medical Practice Solutions, revenue was in line with the same period of the prior year, reaching over BRL 128 million. This lower growth is part of the investment strategy we previously announced, aimed to increase the user base in these two segments. In this quarter, we are already seeing 10% growth on in-Continuing Education students compared to the same quarter of the prior year.

Virgílio Gibbon: In Medical Practice Solutions, we see a 3% growth in both paying users and MAU compared to the previous quarter. Our ecosystem now counts 300,000 users, reflecting continuing meaningful penetration among physicians and medical students across the country. Now, moving to slide number 4, we will discuss the highlights of our three business segments and our corporate achievements. Starting with the Undergraduate segment in medicine course, we saw medical school net average tickets rising by 4% year-over-year. We also continue to deliver strong student base growth momentum in Health Science course. Compared to the previous year, average Health Science students increased by 18%, reflecting the diversification of our health-related undergrad portfolio. In addition, we secured the authorization of 17 medical additional seats in Afya Cruzeiro do Sul on 18 September. This approval reinforce our organic growth runway and supports our ability to expand with predictability.

Virgílio Gibbon: The Continuing Education segment was once again marked by strong growth in our total student base, which expanded 10% in the 9 months of 2026. B2P revenue for the segment grew 4% compared to the same period last year. In Medical Practice Solutions segment, delivered 20% increase in clinical management active payers in 9 months. In addition, B2B revenue grew 4% year-over-year. Lastly, shareholder returns remained a key priority. Our disciplined capital allocation framework continues to create sustainable value for shareholders. At the corporate level, supported by strong cash generation, we returned BRL 459 million to shareholders through dividends and share repurchase in the 9 months of 2026.

Virgílio Gibbon: To conclude corporate context, we are glad to announce that we achieved a AA MSCI ESG rating, becoming the highest rated company in the education sector in Latin America. Afya also has achieved an ESG leader status within the diversified consumer service industry. This result shows the strength of our business model and our ecosystem, while creating the foundations we need to keep growing and unlock the next chapter in the company's history. I will now turn the call over to Luis Blanco, Afya's CFO, to provide further insight into the financial operation metrics. Thank you.

Luis André Blanco: Thank you, Virgílio, and good evening, everyone. Starting with the next slide for discussions of key operational metrics by business unit, starting with the Undergraduate programs. Our medical student base grew by 3% compared to the first nine months of 2025, reaching over 26,000 students, while operating medical school seats increased 5% year over year to 3,785. Our medical school net average tickets increased by 4%, reaching BRL 9,466 in the nine months of 2026. In addition to our Health Science and other Undergraduate programs, revenue for the Undergraduate segments grew by over 7%, totaling BRL 2,642 million. Notably, 85% of this revenue comes from the medical program and 93% from health-related courses, reinforcing our strategic focus and leadership in the sector. On the next page, I will present our Continuing Education metrics. We approach Continuing Education through three main journeys.

Luis André Blanco: Starting with the residency journey, which encompass products focused on the residency preparations. The student base dropped 4% year over year to 9,595 students at the end of the period, but increased 4% quarter over quarter, reflecting the seasonality of this product. In the graduate journey, which focus on specializations, test preparations, and graduate medical education, total students increased 2% to 9,386, supported by continued demands for advanced medical training programs. Lastly, other B2P and B2B offerings continue to grow, with a total students up 17% year over year to 36,345. Continuing Education revenue increased to BRL 209 million in the nine-month period of 2026, compared to BRL 208 million in the same period of 2025, representing a growth of 1%. This performance was primarily driven by B2P revenue, which increased over 4% year over year to BRL 195 million, representing 93% of the Continuing Education revenue.

Luis André Blanco: Meanwhile, B2B revenue totaled BRL 14 million. Moving to the next slide, I will discuss the Medical Practice Solutions operational metrics. Total active payers increased by 2% year over year to approximately 206,000, with clinical management active payers growing 20% to 52,000, reflecting continued penetrations of Afya iClinic. Monthly active users reached 219,000 during the period, down 4% year over year. Medical Practice Solutions revenue reached BRL 128 million in the nine months of 2026, broadly in line with the same period of the prior year. On the next slide, we present Afya ecosystem. We are proud of the meaningful impact Afya continues to make across Brazil healthcare ecosystem. By the end of Q3 2026, over 300,000 users were actively engaging with our service and products, reflecting our solid relevance and reach in medical educational and medical solutions.

Luis André Blanco: Moving forward, I want to discuss our financial overview for Q3 and the nine months of 2026. I am pleased to present another solid set of results for Afya, reflecting the resilience of our business model and our continued focus on sustainable growth and operational efficiency. Revenue for Q3 2026 reached BRL 985 million, a 6% increase from the same period from the prior year. For the nine months of 2026, revenue totaled BRL 2,970 million, up 7% year over year. Adjusted EBITDA reached BRL 434 million in Q3 2026, up 9% from the prior year. For the nine-month period, adjusted EBITDA totaled BRL 1,352 million, up 5% year over year. Adjusted EBITDA margin reached 44% in the quarter and 45.5% in the nine-month period.

Luis André Blanco: The margin expansion in the quarter was primarily driven by higher gross margins in the undergraduate segments and partially offset by gross margins compression in the Continuing Education and Medical Practice Solutions segments, associated with the ongoing investment cycle in both segments, and higher sales and marketing expenses. On the next page, cash flow from operating activities reached BRL 1,333 million in the nine-month period of 2026, compared to BRL 1,291 million in the same period of the prior year, representing a growth of 3%. Cash conversion remained strong at 99.5%, broadly in line with the prior year. Net income for Q3 2026 totaled BRL 171 million, up 7% from the same period of the prior year. For the nine months of 2026, net income reached BRL 634 million, up 7% year over year.

Luis André Blanco: Earnings per share increased BRL 1.88 in Q3 2026, up 10% from the BRL 1.71 in the prior year period, higher than the net income increase, reflecting the executions of our buyback program. For the nine-month period, earnings per share reached BRL 6.98, up 9% from the BRL 6.40 in the nine-month period of 2025. Overall, these results reflect Afya's abilities to continue generating solid cash flow while delivering consistent growth in profitability and shareholder returns. Now, moving to my last two slides, I will cover our gross debt composition and our cost of debt, and our net debt reconciliation. These slides detail the compositions of our gross debt position as of September 2026, covering its maturity profile and average cost of debt.

Luis André Blanco: Afya continues to maintain a solid capital structure and a conservative leverage profile. As of 30 September 2026, gross debt totaled BRL 2.5 billion, compared to the BRL 2.3 billion as of September 2025. At the same time, the average debt duration increased from 1.9 years to 3.7 years, extending our maturity profile in the period. The average cost of debt in 2026 is 15.2% per year, representing approximately 106% of the CDI for the period. On the next page, we can look closely at the net debt variation. Our net debt positions continue to benefit from a solid cash flow from operating activities, which totaled BRL 1,333 million during the period. This largely offsets tax, investments, leases, and interest expenses. As of September 2026, our net debt totaled BRL 1.2 billion.

Luis André Blanco: Our free cash flow to equity reached BRL 629 million in the first 9 months of 2026, including BRL 206 million generated in Q3. It is worth mentioning that Afya disbursed Pillar Two taxations for the first time at the end of July 2026. This strong cash flow generation allowed us to return BRL 459 million to shareholders through dividends and share repurchase during the 9-month period, while reducing our net debt by BRL 117 million. Afya net debt, excluding IFRS 16, divided by the midpoint of the 2026 adjusted EBITDA guidance, is 0.7 times. This concluded our prepared remarks. The 9-month periods of 2026 reinforce what we have consistently demonstrated over time: a resilient business, a focused team, and a strategy that is working.

Luis André Blanco: We remain deeply committed to advancing the physician journey through our integrated ecosystem and confident in our ability to deliver sustainable long-term value for our shareholders, students, and healthcare professionals across Brazil. The strengths of our ecosystems and the resilience of our business model enable us to continue growth and reinforce our ability to achieve our objectives. I will now open the conference for the Q&A session. Thank you.

Renata Couto: If you want to ask a question, please raise your hand. The first question comes from Livia from JP Morgan.

Livea Mizobata: Hi, Virgílio, Luis Blanco, Renata. Thank you for the opportunity for making questions. I want to have 2 questions here. The first one is on the medical segment. Could you give us an update on the competitive environment, especially for the H1 of next year intake? I know it is a little bit early at this point, but if you could give us some color, it would be great. If you could also comment a little bit on how you see the dynamics for tickets next year. The second one, we would like to better understand the elements behind the expansion of gross margin in the undergraduate segments. Thank you.

Virgílio Gibbon: Hi, Livia. It's Virgílio. Thanks for your question. As you said, it's very early in the process to give a call or how we will be doing take for 2027 first semester. Regarding tickets, we passed 5.7% over our gross tuition to next year. We are in very beginning, so kind of optimistic based on what we did on the second semester of 2026. This is as regard the competition and the trend for 2027. About the gross margin on Undergraduate, we saw in this quarter very good results coming from Undergraduate. We are 100 bps over the same quarter last year, and basically comes also for Undergraduate. The gross margin expanded.

Virgílio Gibbon: Most of them are very good results also on medical, but also on health programs that we continue to have very high growth on other health programs on our campuses, diluting fixed costs and also improving the number of students per class, also combining more health-related disciplines between programs, what help us to minimize the faculty cost. I think this is the overall reason coming from a better gross margin on this Q3.

Livea Mizobata: Perfect. Very clear. Thank you.

Renata Couto: Next question comes from Flavio from Bank of America.

Flavio Yoshida: Good evening, everyone. Thanks for taking my questions. I have two on my side. The first one is on ENAMED. I was wondering if you have already had access to any preliminary results or insights from this year's exam. Based on what you have seen so far, do you guys anticipate having to increase investments or costs to better prepare your students for the ENAMED exams in the upcoming years? My second question is on Continuing Education. We have been informing that the student base growth is not translating into a proportional revenue growth, right? I think you guys already mentioned that there is a mix shift towards short duration and lower ticket courses. My question here is on when should we expect the monetization of this growing student base to evolve, or when should we expect revenues per student to stabilize?

Flavio Yoshida: Also, if you want to continue education, if you could explain what is going on on the B2B revenues that has been increasing at 30% year over year. Thank you.

Virgílio Gibbon: Hi, Flavio. Actually, it is four questions here, at least that I took the note here. First is the preliminary ENAMED results. We do not have any clue from the Ministry of Education yet. Everything that we have is based on our internal assessment because we got back the answers from our students. We make the correction and all the estimative, how is the average of our student compare to the previous ENAMED exam, and we were almost 20 percentage points above. It was a very good result. Actually, it was 18 percentage points on a simple average. Also, doing the normalization, considering our distribution, our student base, we are also having a much better proficiency rates on every campuses. But it is still a preliminary. We are not comparing our student to the entire student base in Brazil. We cannot take this as a consideration. Second, regard the costs.

Virgílio Gibbon: As you saw, we increased our margins, and we improve our gross margins. We did not have any additional cost from ENAMED. We are doing 100% internally. We have all the features now that we have the information. We run at least 11 mocks for every campuses, and we did a lot of homework for this new step of this new ENAMED, that the result is at least expected to be released in December. Your third question is about the Continuing Education that we are seeing and growth on the student, but revenue is not coming at the same proportion. Yes, we are growing faster the student base. We are seeing a more critical in terms of conversion, price-sensitive physician to enroll in a long duration programs.

Virgílio Gibbon: The mix effect here is that we have much more student applying for short duration programs, more related to procedure, new technicals for some specialties. The consequence direct on that is that the revenue is not come because the tuition is much lower. That is the reason of Continuing Education. When we will see a same stores in some, maybe 2020, not in 2026, but in 2028, we are aiming to go north in 1 single digit. It is what we are aim on Continuing Education 2027. On the B2B revenues, we have a mix effect here. We are seeing a strong growth on the traditional pharma-related contract, but a reduction on the other side, on the other types of B2B contracts related also for providers and other type of institution.

Virgílio Gibbon: We are seeing that we are a bit more flat this year over in 2026, but the sales volume is getting a little bit higher. Expecting better results for 2028. Q4 will be actually the same trend that we are seeing for the entire year. Okay? I think I capture all the 4 questions, not 2.

Luis André Blanco: Just if I may add something here, Virgílio, to Flavio. In the B2B side from Educon, where we see the decrease year over year, it is more related to the test prep market that has changed a lot during the year, Flavio, because of the ENAMED. This dynamic changed a lot of these years, and we think that is opportunity for the next years to recover it with this market, with this new ENAMED phase that we are going to have. The 3 phases test, 1 for the second year, the fourth year, and the last test in the sixth year. I think it is opportunity to recover these B2B signs from the Educon.

Renata Couto: Regarding the B2B of SPM, is the one that we are seeing the sales increasing.

Flavio Yoshida: Okay. All right. Thank you a lot.

Renata Couto: Of course. Next question comes from Felipe Amancio from Itaú BBA.

Felipe Amancio: Hi. Good evening, everyone. Two questions from my side. The first one is on profitability. We noticed a margin increase in the quarter, mostly driven by the Undergraduate. You have already commented about this in your last answer, but if you could comment a bit better, if this changes your expectations for profitability gains for next year, and also, what are the main levers that you envision in this segment? My second question is also on profitability. We noticed here a greater net revenue decrease on Continuing Education and Medical Practice Solutions. I would like to understand how much of this profitability increase that we observed this quarter could be explained by this revenue mix. Thank you.

Luis André Blanco: Hi, Felipe. It is Blanco here. I will take the questions. The first regarding the profitability for these years, we will deliver the guidance that we provide to the market in the beginning of the year. We had a decrease.

Luis André Blanco: In the first two quarters, we have these 100 bps above this Q3, but all of it, we are going to perform the year delivering the guidance that we provided at the beginning of the year. Regarding the margins from 2027 ahead, we will deliver the guidance for 2027 when we release the 2026 results in March. Regarding the mix of segments affecting the profitability in general, what we have is that undergraduate segments represents roughly 86% of our net revenue. So, if we get more profitability coming from the segments, it will cover the participation from Educon and SPM that we have, the decrease in the period. That is why these major participations from the undergrad more than covers the margins that were down in Educon and SPM.

Felipe Amancio: Perfect. Thank you for the answers.

Renata Couto: Thank you. The next question comes from Lucas Nagano from Morgan Stanley.

Lucas Nagano: Hi, Renata. Virgílio, Luis André Blanco, thanks. We have two questions. The first is related to working capital. There has been an upward trend in receivable days. Is this explained by higher share of FIES and private funding? If yes, should we expect this trend to continue into next year? The second is related to CAPEX. There is a reasonable gap between year-to-date CAPEX and the lower end of the guidance. The question is, if this guidance is realistic, or if not, is it a matter of postponing investments, or should investments be indeed lower? Thank you.

Luis André Blanco: Hi, Lucas Nagano. It's Luis Blanco. I want to take your questions. Regarding the working capital, what is pushing our working capital is the trade receivables, and inside of trade receivables, we are having increase in the FIES. So we have an increase of 64% in FIES, 64% of the FIES, if you compare to December. This is roughly BRL 90 million in the periods that these push our receivables up in the periods. Talking ahead about FIES, we do not have the expectations to increase the positions of FIES. We are around 22% of the medical students using FIES as of the Q3. We do not expect to increase these positions going ahead. Regarding CAPEX, you are right.

Luis André Blanco: We are a little bit lower than our expected CAPEX for the period, but our expectations that we are going to achieve the guidance that we provided that is between BRL 340 million to BRL 380 million in the year.

Virgílio Gibbon: Just to add a point here, Lucas, regarding the FIES. When you compare the schedule of FIES on the H2 2026 with the H1 or the previous year, we are in a much later trend. All the amendments are still working, being due by the end of this month. So, the growth, the increase on the working capital coming from FIES, I think it's a trend for the entire sector, given the late schedule for the amendments and the renewal of all the contracts coming from FIES. So, that's also another. For next year, we expect it to be flat or a little bit lower in terms of FIES for 2028.

Luis André Blanco: But-

Virgílio Gibbon: Okay

Luis André Blanco: All of that, Lucas Nagano, just important just to highlight that even that with this increase in receivables, if we compare our cash flow from operating activities with our EBITDA, our cash conversions is 100%. In the first 9 months, of course.

Lucas Nagano: Okay. Thank you.

Renata Couto: Okay. Since we do not have any more questions, I thank you all for participating. Thank you and have a good night. Goodbye.

Q3 2026 Afya Ltd Earnings Call

Demo

Afya

Earnings

Q3 2026 Afya Ltd Earnings Call

AFYA

Thursday, November 12th, 2026 at 10:00 PM

Transcript

No Transcript Available

No transcript data is available for this event yet. Transcripts typically become available shortly after an earnings call ends.

Want AI-powered analysis? Try AllMind →

Earnings analysis guides

Methods for extracting KPIs and checking source support when reviewing an earnings call.

Browse all earnings calls